This bill simplifies the approval process for biosimilar drugs - medicines that are highly similar to, but not identical to, existing biologic drugs. It amends the Public Health Service Act to clarify when biosimilars are deemed "interchangeable" with the original drug (allowing pharmacists to substitute them without a doctor's specific order), adjusts exclusivity periods for existing biosimilars, and sets a 60-day transition period after enactment. The bill also requires the FDA to update its guidance documents within 18 months to reflect these changes. This directly affects pharmaceutical companies developing biosimilars, the FDA in its review process, and ultimately patients seeking more affordable treatment options.
The MAPS Act requires the Secretary of Health and Human Services to update and maintain an Essential Medicines List including drugs critical for national security, public health emergencies, chronic conditions, and military readiness. It mandates annual risk assessments identifying supply chain vulnerabilities, particularly drugs sourced over 50% from high-risk foreign suppliers like China, and compiles data on manufacturing locations and shortages. The bill directs HHS to map U.S. pharmaceutical supply chains from raw materials to finished products, using data analytics to identify national security threats, and report findings annually to Congress. This directly affects federal agencies (HHS, Defense), drug manufacturers, and supply chain stakeholders through mandatory reporting and transparency requirements.
S 529, the Capping Prescription Costs Act of 2025, limits how much individuals and families must pay annually out-of-pocket for prescription drugs under most health insurance plans. Starting in 2026, it caps these costs at $2,000 per person or $4,000 per family per year, with automatic annual adjustments using the medical care inflation rate (CPI). This applies to both individual health plans (under the Affordable Care Act) and group health plans (like employer-sponsored coverage), as amended across multiple federal laws. The bill does not change drug prices but directly affects millions of health plan enrollees by setting a maximum annual cost for covered prescriptions.
This bill modernizes how the FDA inspects facilities manufacturing biosimilar drugs (similar but not identical versions of biologic medicines) in the U.S. It requires the FDA to hold a public meeting and issue a report on expanding international inspection agreements, update inspection tools to increase remote assessments (like virtual site reviews), and develop a strategic plan within a year to address staffing and communication challenges specific to biosimilar facility inspections. The bill directly affects FDA inspectors, biosimilar drug manufacturers, and the FDA's inspection processes for domestic facilities. It focuses on improving inspection efficiency and communication without changing drug approval standards or safety requirements.
HR 5526, the Biosimilar Red Tape Elimination Act, streamlines the U.S. Food and Drug Administration’s (FDA) process for approving biosimilar drugs that can be used interchangeably with brand-name biologic medications. It establishes a 60-day transition period after enactment to clarify when biosimilars are deemed "interchangeable" with reference drugs, preserving existing exclusivity periods for products licensed before the law’s passage. This affects pharmaceutical manufacturers developing biosimilars, the FDA (which must update its guidance within 18 months), and healthcare systems seeking lower-cost treatment options. The bill removes redundant language from existing laws and ensures the FDA’s approval standards for biosimilars remain unchanged, focusing on regulatory clarity rather than altering drug safety or efficacy requirements.
HRES 928 is a non-binding House resolution affirming support for aligning U.S. prescription drug prices with those in other developed nations, commonly called "most-favored-nation" pricing. It states that U.S. patients should not pay more for the same drugs than citizens in comparable countries, citing data showing U.S. drug prices are 2.78 times higher than in other nations and that 21% of adults skip prescriptions due to cost. The resolution supports policies to reduce drug costs, including aligning U.S. pricing with international benchmarks and expanding Medicare negotiation, but does not create new laws or alter existing programs. It directly addresses all U.S. patients affected by high drug costs, reflecting bipartisan interest in lowering prices as noted in President Trump’s 2025 executive order.
This bill sets annual reference prices for prescription drugs based on the lowest prices in specific countries (like Canada, UK, and Germany), preventing manufacturers from charging more than this price for drugs covered under major federal health programs. It directly affects Medicare, Medicaid, VA care, TRICARE, and other federal health programs by capping drug costs at the reference price. Manufacturers must sell drugs at or below this reference price to all patients, including those without insurance, with civil penalties of up to five times the revenue difference for non-compliance. Collected penalties fund drug research through the National Institutes of Health.
This bill modifies requirements for approving biosimilar drugs (follow-on versions of biologic medicines). It removes previous mandatory assessments of immunogenicity or clinical efficacy for biosimilar licensure, instead allowing the FDA to require such studies only when the agency provides written justification to the applicant. The change applies to new biosimilar applications submitted after the bill's enactment. It directly affects drug manufacturers seeking FDA approval for biosimilars and the FDA's review process, aiming to streamline approvals while maintaining safety standards.
The SMART Prices Act (S 1836) changes how Medicare negotiates drug prices. It increases the number of drugs eligible for negotiation from 15 to 50 per year starting in 2028, shortens the time drugs must be the sole source for eligibility from 7 to 3 years, and adjusts price ceiling percentages for negotiated drugs (e.g., raising the maximum fair price from 75% to 76% for some drugs). These changes directly affect Medicare Part D beneficiaries and pharmaceutical companies by altering the negotiation process and pricing caps. The bill modifies existing Medicare drug pricing rules without creating new programs, applying to initial price negotiations beginning in 2028.
S 2903, the Safe Step Act, requires health insurance plans and employers offering health coverage to establish a clear, timely process for patients or doctors to request exceptions when step therapy protocols (where insurers require trying cheaper drugs first) would harm a patient. It mandates approval for exceptions if prior drugs failed, delay would cause severe harm, a drug is unsafe, or a patient is stable on their current medication. Plans must respond to requests within 72 hours (or 24 hours in emergencies) and cover the requested drug without extra cost-sharing. The bill also requires annual reports to the government on exception requests, approvals, denials, and trends by medical condition or specialty. This directly affects patients on health plans with step therapy, their doctors, and the insurers managing those plans.
